Tags & Categorías

Rethinking the Patient Perspective on Biosimilars

Often left out of the discussion about switching to biosimilars is the perspective of a particularly key stakeholder group: patients. During the BioTe...

More Than a Decade After the First Biosimilar, the Biosimilar Regulatory Landscape Is Increasingly C...

During the first day of the BioTech Pharma third annual Biosimilars and Biologics Summit, held March 21 to 22 in Porto, Portugal, Barbara Valenta-Sing...

Regulator Explains How Denmark Has Achieved Its Biosimilar Success

Nikolai C. Brun, MD, PhD, chief medical officer and director of the division of medical evaluation and biostatistics at the Danish Medicines Agency, s...

Positive Results for Celltrion's Proposed Biosimilar Bevacizumab in Phase 1 Trial

According to the investigators, their data support the further development of CT-P16 as a bevacizumab biosimilar.

Alvotech Enrolls First Patient in Phase 3 Study of Proposed High-Concentration Biosimilar Adalimumab

Drug maker Alvotech announced today that it has begun enrollment for its phase 3 clinical study of AVT02, a proposed adalimumab biosimilar referencing...

Asturias crea una guía para potenciar el uso de genéricos y biosimilares

El documento incluye los medicamentos necesarios para cubrir las patologías generales de los pacientes

No Difference in AEs Between Sandoz's Ziextenzo and Reference Pegfilgrastim

Among the data presented to regulators for the product’s approval were those arising from a phase 1 pharmacokinetic and pharmacodynamic study in hea...

Sandoz lanza en España Zessly, su biosimilar de infliximab

Sandoz ha lanzado al mercado español su medicamento biosimilar de infliximab, Zessly, un fármaco que está disponible para ocho indicaciones incluid...

Fewer Than Half of Oncologists in ESMO Survey Report Using Biosimilars in Clinical Practice

Only 49.0% of prescribers reported that they use biosimilars in routine clinical practice, with more respondents from the Asia–Pacific region (56.3%...

Early EU Experience Shows Positive Results for Samsung Bioepis' Biosimilar Adalimumab

The launch of biosimilar adalimumab products in the European Union in October 2018 was an important moment for health systems in serious need of cost ...